Grant Pharmacy
Hassle-Free Shopping
Live healthy
Care for your health needs
Affordable prescription drugs to all people
We respect our customer privacy
Reorder Coupons

Total Privacy

Privacy

Enjoy private and confidential shopping with complete peace of mind.

Total Security

Security

Your personal information is never shared. We follow strict security standards to keep your data safe and confidential.

Home / Gastro Health /   Udimarin Forte Sr (Ursodeoxycholic Acid) 450 Mg

Udimarin Forte Sr (Ursodeoxycholic Acid) 450 Mg

Udimarin Forte Sr (Ursodeoxycholic Acid) 450 Mg

Category:Gastro Health
Active substance:Ursodeoxycholic Acid 450 Mg
Prescription:Upload it in Checkout.
Manufacturer:Fourrts India Laboratories Pvt Ltd
Customer rate:
Share
Save

Udimarin Forte Sr (Ursodeoxycholic Acid) 450 Mg

PackageOur PricePer PillActions
30 Tabs
$94.80
$3.16
Air Mail
60 Tabs
$184.80
$3.08
Air Mail
90 Tabs
$270.00
$3.00
Air Mail
120 Tabs
$350.40
$2.92
Air Mail
180 Tabs
$511.20
$2.84
Air Mail
270 Tabs
$745.20
$2.76
Air Mail
360 Tabs
$964.80
$2.68
Air Mail

Usage

Udimarin Forte SR (Ursodeoxycholic Acid) 450 Mg

 

Introduction

Udimarin Forte SR (Ursodeoxycholic Acid) 450 Mg is an orally administered sustained-release medicine belonging to the bile acid preparations group and comprising 450 mg of ursodeoxycholic acid (also known as ursodiol or UDCA). It might be recommended to treat selected cases of cholestatic liver diseases and selected cases of cholesterol gallstones when treatment with UDCA is clinically indicated.

The term 'SR' refers to sustained-release. This characteristic is crucial since the system of release of the active component might be affected by crushing, chewing or improper splitting. Udimarin Forte Sr is a foreign brand; there is no evidence that FDA-approved ursodiol products contain this exact brand.

 

What is Udimarin Forte SR (Ursodeoxycholic Acid) 450 Mg

Udimarin Forte Sr 450 mg consists of Ursodeoxycholic Acid, which is a hydrophilic bile acid occurring naturally in small quantities in human bile. This pharmaceutical belongs to the therapeutic class of bile-acid preparations.

The exact release profile, dosing intervals, the purpose of the score line and its divisibility are to be confirmed by the manufacturer's labeling information for the current batch.

Udimarin Forte Sr Ursodeoxycholic Acid includes the same active ingredient as the common immediate-release ursodiol tablets. However, common immediate-release ursodiol tablets cannot be considered equivalent to a sustained-release 450 mg preparation.

How It Works

The ursodeoxycholic acid mechanism of action depends on the specific condition to be treated. In case of cholestatic liver disease, UDCA increases the fraction of hydrophilic bile acids in the bile-acid pool. Consequently, more hydrophobic bile acids responsible for damage to hepatocytes and bile duct cells are displaced. UDCA also stimulates bile secretion and provides cytoprotective action.

As for the susceptibility cholesterol gallstones, UDCA inhibits cholesterol secretion from the liver and reduces cholesterol absorption in the intestine. This leads to less saturated bile and higher probability of gradual dissolution of the proper gallstones.

This mechanism of action does not mean that the medicine acts as a universal liver cleansing agent. There is a number of factors required to achieve the positive results of UDCA treatment.

Why It Is Prescribed

U.S. labeling-approved ursodeoxycholic acid tablet uses vary according to the country of origin, dosage form and authorized indication. Immediate-release ursodiol tablets are approved for treating primary biliary cholangitis. Selected ursodiol capsules are indicated for selected cholesterol gallstones and gallstones prevention during rapid weight loss.

According to regional labeling and practice of specialists, UDCA may be recommended for:

Treating primary biliary cholangitis as a first-line long-term therapy

Small, radiolucent, noncalcified cholesterol gallstones when surgery is impossible or contraindicated

Selected cholestatic liver/biliary diseases

Certain pediatric hepatobiliary diseases under specialist supervision

Intrahepatic cholestasis of pregnancy when prescribed by an obstetric and liver care teams

UDCA cannot dissolve all types of gallstones. Calcified, radiopaque, pigment and certain large stones are unlikely to be dissolved. Acute gallbladder inflammation, bile duct infection, bile duct obstruction, gallstone pancreatitis or any other indication for surgical intervention generally requires a different approach to the treatment.

Why the SR Formulation Matters

Udimarin Forte Sr UDCA is made in a special way to distinguish it from a common immediate-release formula. Sustained-release tablet delivers the medicine gradually instead of making it fully available immediately.

Crushing or chewing of an SR tablet might affect its release properties. Splitting might be undesirable if it is not specified by the manufacturer as a possible option to administer the tablet.

The SR formula does not mean that this medicine is clinically stronger than all immediate-release medicines. It describes the way the active ingredient is delivered. Neither it means that one tablet is a right dose for all patients.

Patients comparing an ursodeoxycholic acid brand name product should pay attention to the formula, dosage form and release type of each drug. Only matching the active ingredient and the total quantity in mg is not enough if the formulas differ.

How to take this medication

Udimarin Forte Sr 450 mg should be taken strictly according to the prescription and manufacturer's instructions included in the current pack of pills. The pill should be swallowed with water. It is recommended not to crush, chew or split it unless the current label says otherwise.

Dietary recommendations should be provided in the product-specific label and prescription. While FDA-approved immediate-release ursodiol tablets for primary biliary cholangitis are taken with food, it should not be assumed regarding this sustained-release product.

If a dose was missed, it should be taken when it is remembered unless the next dose is near. If the next dose is soon, it is better to skip the missed dose and resume the treatment according to the schedule. Double doses are prohibited.

Cholestyramine, colestipol and aluminum-containing antacids could lower the absorption of UDCA. One needs to find a proper separation schedule when taking one of these products.

How It Works Inside the Body

Orally ingested ursodeoxycholic acid (udca) goes to the liver through the portal circulation. Liver extracts a significant part of it during the first passage, conjugates with glycine or taurine and secreted it into bile.

Conjugated UDCA enters the intestines with bile and can be reabsorbed back into the liver via enterohepatic circulation. Some part of it is metabolized by intestinal bacteria and turns into lithocholic acid. Poorly absorbed material and metabolites are eliminated through feces, urine elimination is minimal.

With repeated administration the share of UDCA in the bile-acid pool grows due to the fact that it passes between the liver, bile and intestines. Therefore, the clinical persistence of this medicine cannot be estimated by the half-life.

The SR tablet can influence the speed of absorption of the active ingredient. The exact pharmacokinetic parameters for Udimarin Forte SR need to be found in the manufacturer's information and should not be obtained from immediate-release products.

Dosage Explanation

Ursodeoxycholic acid 450 mg refers to the content of one sustained-release tablet. This parameter does not establish the number of tablets and dosing schedule.

U.S. immediate-release tablet labeling suggests 13-15 mg/kg/day in the case of primary biliary cholangitis.

U.S. ursodiol capsules labeling indicates approximately 8-10 mg/kg/day for gallstone dissolution.

Dosage requirements based on the weight of the patient may not be divisible into 450 mg.

A 450 mg SR tablet cannot be automatically replaced by 250 mg, 300 mg or 500 mg immediate-release tablets.

Two products containing the same total number of milligrams of UDCA can deliver the medicine differently.

Any adjustments involving an SR tablet should be done according to the prescription and manufacturer's labeling.

Kidney elimination is not the main factor influencing the dose due to the fact that elimination of the medicine is primarily fecal. The presence of severe cholestasis and advanced liver/biliary disease might influence the elimination of the medicine.

What to Expect During Treatment

UDCA does not provide an instant relief of the symptoms. In the case of primary biliary cholangitis, the response is estimated on the basis of bilirubin, alkaline phosphatase, gamma-glutamyl transferase, AST, and ALT levels. According to U.S. immediate-release tablet labeling, monthly testing is suggested in the first 3 months and every six months later. However, this regime may vary regionally.

Improvement of symptoms does not guarantee the control of the underlying disease. Similarly, persistent symptoms do not guarantee the lack of response. The current PBC guidelines consider the biochemical response, disease stage and fibrosis risk along with the symptom burden.

Gallstone dissolution usually takes several months. Proper stones might need up to 6-24 months of therapy and complete dissolution does not happen in everyone. Imaging is necessary since symptoms cannot confirm the disappearance of the stone. Recurrence of the gallstone is possible after successful dissolution.

Precautions and warning

UDCA is contraindicated in the case of complete biliary obstruction and patients with hypersensitivity to ursodiol, bile acids or a product ingredient. This medicine is not effective in dissolving calcified, radiopaque and pigment gallstones.

Patients with Crohn's disease, intestinal obstruction, impaired gastrointestinal motility or previous GI surgery should inform the prescriber about their full medical history.

According to the current U.S. tablet labeling, human pregnancy data are not sufficient to evaluate the risk of adverse effects to fetus and miscarriage. The therapy of pregnant women should be managed by the obstetric and liver-care specialists. Data regarding breastfeeding are limited. No information about safety and efficacy in pediatric population is available under U.S. labeling; however, some jurisdictions allow specialist-directed use of the medicine in certain pediatric indications.

Side Effects

Common ursodeoxycholic acid side effects may include:

  • Diarrhea
  • Loose stools
  • Mild abdominal discomfort or pain
  • Nausea/indigestion
  • Constipation
  • Headache/dizziness
  • Mild pruritus or rash
  • Thinning or loss of hair

Not every patient develops these symptoms. They tend to improve over time and do not require further actions from patients. The patients experiencing constant and bothersome side effects should seek help from a health care provider.

Drug Interactions

Cholestyramine and colestipol: These medicines reduce UDCA absorption by binding bile acids in the intestine.

Aluminum-containing antacids: Aluminum reduces the amount of bile acids that can be absorbed.

Estrogens and oral contraceptives: Increase the cholesterol secretion into bile and may antagonize gallstone dissolution.

Clofibrate and lipid-modifying medicines: May stimulate formation of cholesterol-rich bile and decrease chances of successful gallstone dissolution.

Medicines causing cholestasis: They may reduce the effectiveness of UDCA or complicate interpretation of liver test results.

Additional therapy for primary biliary cholangitis: Another therapy may be considered in the case of inadequate UDCA response, but it requires a specialist consultation.

Understanding Product Availability

An investigation of the ursodeoxycholic acid market might show many strengths, manufacturers, tablets, capsules and sustained-release formulas. None of these products can be considered the same without verification of their complete manufacturer labels.

In particular, common ursodeoxycholic acid tablets cannot be substituted for Udimarin Forte Sr tablet by matching the total number of milligrams. The SR formula and the dosing interval should be taken into account.

Practical Tips for Better Results

Swallow the tablet intact unless the current label allows dividing it. Administer the tablet at the prescribed time and separate properly the intestinal bile-acid binders.

Visit your doctor for the scheduled blood tests even if your symptoms improved. In case of UDCA prescription for gallstones, visit your doctor for scheduled imaging as well since it confirms the effectiveness of the therapy.

Patients with a prescription who wish to purchase Udimarin Forte Sr 450 mg online through Grant Pharmacy should ensure that the selected product has the SR formula and the right strength. To check the current inventory, prescription requirements, delivery availability to your destination and other information concerning this order, one can contact Grant Pharmacy. Delivery to your address is guaranteed when the prescription is validated by the pharmacist and pharmacy rules permit it. Order this product through Grant Pharmacy and contact Grant Pharmacy if the name, SR formula, strength and dosage form do not match the prescription.

Storage Instruction

Store the tablets in the original, tightly closed container.

Keep them at room temperature unless the manufacturer recommends another storage.

Protect the medicine from excessive heat, humidity and light.

Do not store the medicine in a wet bathroom.

Store all tablets away from the reach of children.

Do not use tablets that are expired.

Do not store divided or crushed tablets if it is not allowed by the manufacturer.

FAQs

What is Udimarin Forte SR 450 mg used for?

It may be used to treat selected cholestatic liver conditions or gallstones if it is clinically justified; the exact indication should be confirmed from the prescription and manufacturer's label.

What does SR mean in Udimarin Forte SR?

SR means sustained release. The tablet is supposed to release its active component gradually; therefore, it should not be crushed, chewed or divided unless the manufacturer recommends it.

Is Udimarin Forte SR the same as ordinary ursodiol?

It has the same active ingredient, but the mechanism of release differs from ordinary immediate-release formula. The products should not be used interchangeably without confirming the formulation and scheduling.

Can Udimarin Forte SR be used for fatty liver?

UDCA is not a routine treatment of metabolic dysfunction-associated steatotic liver disease. The cause of liver abnormality should be determined before prescribing any medicine.

Can one 450 mg tablet dissolve gallstones?

Gallstone therapy is based on the weight of the patient; besides, only selected gallstones are treated with this medicine. One tablet might not be equal to the prescribed daily dose. Scanning is necessary to determine the response to the therapy.

Can I stop the therapy when my liver tests become normal?

Normal laboratory results might indicate response to the treatment, but it does not mean that a chronic condition such as primary biliary cholangitis is cured. The therapy is usually continued unless the prescribing specialist discontinues it.

Final Conclusion

Udimarin Forte Sr 450 mg combines UDCA treatment with sustained-release delivery system. The distinctive feature of this medicine is not only the 450 mg strength, but the formula of the tablet.

The tablet should be swallowed and administered according to the instructions from the manufacturer. Weight-based therapy, interactions management, laboratory tests and gallstone scanning are still important in spite of the use of sustained-release formula.

Medical reviewed by Grant Pharmacy Pharmacists Medical Team

Medical References

U.S. Food and Drug Administration (FDA) – URSO 250 and URSO Forte Tablets, Prescribing Information

https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020675s028lbl.pdf

DailyMed – Ursodiol Tablets, Prescribing Information

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=55c1556b-8b47-479a-979b-fd61bdd27c7f

DailyMed – Ursodiol Capsules, Prescribing Information

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6be8e383-37fa-4e0a-b9fc-3976a8be1d2f

MedlinePlus – Ursodiol Drug Information

https://medlineplus.gov/druginfo/meds/a699047.html

Mayo Clinic – Ursodiol Oral Route

https://www.mayoclinic.org/drugs-supplements/ursodiol-oral-route/description/drg-20066618

National Health Service (NHS) Cheshire and Merseyside – Ursodeoxycholic Acid Prescribing Support Information

https://www.cheshireandmerseysideformulary.nhs.uk/docs/files/ursodeoxycholic_psi.pdf

PubMed – AISF Practice Guidance on the Treatment of Primary Biliary Cholangitis: 2026 Update

https://pubmed.ncbi.nlm.nih.gov/42493321/

 

Medical Disclaimer: The information provided on this page is for general informational purposes only and should not be considered medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before using any medication or making healthcare-related decisions. Any reliance on the information provided is solely at your own risk. If you have any questions or concerns regarding the content on this website, please contact our administration team for assistance.

Author Details

Last updated 24 Sept 2026 | 06:16 AM (IST)

Reviews (0)

User Reviews

0.0
(0 Reviews)
5 stars
0
4 stars
0
3 stars
0
2 stars
0
1 stars
0

No reviews

Lowest Price Medicine
Price Match Guarantee
Medications as Promised

Newsletter